Business Services Industry
U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent
Business Wire, April 30, 2008
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response to a request by a law firm that represented the generic company Ranbaxy Laboratories Limited. The patent, which expires in March 2010 (including pediatric exclusivity), was previously the subject of litigation against Ranbaxy, in which Pfizer prevailed in both the trial and appeal courts.
The company noted that it is pleased with the decision, which affirms the company's position that the patent was properly granted.
Most Recent Business Articles
- How do I determine my retainer fee?
- Why fly solo when an executive assistant can accelerate your CLNC® business?
- The CLNC® mentors held the key to my first case and to my CLNC® success
- Atlanta CLNC® 6-day certification seminar photo galleryplus sign up today for spring 2009 to save $100.00
- Speak to a full-time practicing CLNC® consultant
Most Recent Business Publications
Most Popular Business Articles
- Using object-oriented analysis and design over traditional structured analysis and design
- Big Fish Games Migrates Upstream to Fisher Plaza; High Growth Online Gaming Firm Vaults Fisher Plaza Occupancy Rate Above 90%
- Top of the line: some of the world's most well-respected doctors practice in South Florida. A guide to choosing the best physician specialists - Top Doctors in South Florida
- Sand filter basics: high-rate sand filters can be confusing for those new to the business. Understanding valve modes is the key
- BEHR Paints Introduces a Colorful New Way to Paint and Prime All in One with BEHR Premium Plus Ultra™ Interior
Most Popular Business Publications
Content provided in partnership with http://findarticles.com/source//

